KIORA PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: August 7, 2026 | By: | /s/ Brian M. Strem, Ph.D. |
|---|---|---|
| President and Chief Executive Officer(Principal executive officer) | ||
| Date: August 7, 2026 | By: | /s/ Melissa Tosca |
| Chief Financial Officer(Principal financial and accounting officer) | ||
EXHIBIT INDEX
The following exhibits are filed as part of this Quarterly Report on Form 10-Q. Where such filing is made by incorporation by reference to a previously filed document, such document is identified.
| ExhibitNumber | Description of Exhibit |
| 4.1 | Form of Pre-Funded Warrant (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on April 7, 2026 and incorporated by reference thereto) |
| 4.2 | Form of Tranche A-1 Warrant (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on April 7, 2026 and incorporated by reference thereto) |
| 4.3 | Form of Tranche A-2 Warrant (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on April 7, 2026 and incorporated by reference thereto) |
| 10.1† | Form of Securities Purchase Agreement, dated as of April 3, 2026, among Kiora Pharmaceuticals, Inc. and the purchasers named therein (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on April 7, 2026 and incorporated by reference thereto) |
| 10.2† | Form of Registration Rights Agreement dated as of April 3, 2026, among Kiora Pharmaceuticals, Inc. and the holders named therein (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on April 7, 2026 and incorporated by reference thereto) |
| 31.1 | Certification of principal executive officer pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | Certification of principal financial and accounting officer pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1* | Certification of principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2* | Certification of principal financial and accounting officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | XBRL Instance Document (embedded within the Inline XBRL document) |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act.
† Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.